Atara Biotherapeutics (NASDAQ:ATRA) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report report published on Wednesday morning,Benzinga reports.

Several other research analysts also recently issued reports on ATRA. Canaccord Genuity Group dropped their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, January 17th. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Finally, RODMAN&RENSHAW upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, December 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ:ATRA opened at $6.89 on Wednesday. The stock’s 50-day moving average is $12.16 and its 200-day moving average is $9.97. The company has a market cap of $39.69 million, a P/E ratio of -0.27 and a beta of 0.51. Atara Biotherapeutics has a 52-week low of $5.40 and a 52-week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the business posted ($16.50) EPS. As a group, equities analysts predict that Atara Biotherapeutics will post -9.86 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several large investors have recently modified their holdings of the stock. Vestal Point Capital LP boosted its stake in Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares during the period. FMR LLC boosted its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. State Street Corp grew its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth about $79,000. 70.90% of the stock is currently owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.